Kunming, China

Wenlie Peng

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Jiuzhitang Co., Ltd.. Active years: 2020.


% Patents Active = 100.0

 

Average Co-Inventor Count = 15.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Wenlie Peng

Introduction

Wenlie Peng is a notable inventor based in Kunming, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds for medical applications. His work focuses on addressing thrombotic diseases, which are critical health concerns worldwide.

Latest Patents

Wenlie Peng holds a patent for a Fuc3S4S substituted oligoglycosaminoglycan and its preparation method. This invention is characterized by a weight-average molecular weight (Mw) of approximately 4.5-9 kD. The patent details a pharmaceutical composition that includes this oligoglycosaminoglycan, along with its preparation method and potential uses in creating medicines aimed at preventing and/or treating thrombotic diseases. He has 1 patent to his name.

Career Highlights

Wenlie Peng is associated with Jiuzhitang Co., Ltd., a company known for its focus on innovative healthcare solutions. His role at the company has allowed him to contribute to significant advancements in pharmaceutical research and development.

Collaborations

Wenlie has collaborated with notable colleagues, including Jinhua Zhao and Jinxing He. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries in the field.

Conclusion

Wenlie Peng's contributions to the pharmaceutical industry through his innovative patent demonstrate his commitment to advancing medical science. His work not only addresses critical health issues but also showcases the importance of collaboration in driving innovation forward.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…